Related Experiment Videos
Lipid-lowering effects of lovastatin in CAPD patients
R H Jacobs1, S M Lal, K D Nolph
1Division of Nephrology, University of Missouri Health Sciences Center, Columbia.
Insights
Lovastatin therapy showed moderate lipid reduction in some continuous ambulatory peritoneal dialysis patients. However, this treatment was not universally effective for lowering cholesterol and triglycerides in this study group.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Continuous ambulatory peritoneal dialysis (CAPD) is associated with increased cardiovascular risks.
- Hyperlipidemia is a significant contributor to cardiovascular disease in CAPD patients.
- Targeting lipid abnormalities is crucial for managing cardiovascular morbidity in this population.
Purpose of the Study:
- To evaluate the efficacy of lovastatin in reducing serum lipid levels in CAPD patients.
- To assess the effectiveness of a 20 mg/day dosage of lovastatin.
- To determine if lovastatin can improve lipid profiles in patients with persistent hyperlipidemia despite dietary interventions.
Main Methods:
- Retrospective study design.
- Inclusion of 8 CAPD patients with serum cholesterol/triglycerides > 240 mg/dL on a low-cholesterol diet.
- Administration of lovastatin 20 mg/day for 6 months.
Main Results:
- Moderate reductions in total cholesterol and triglycerides were observed in 2 out of 8 patients.
- Lovastatin at 20 mg/day was well-tolerated by all participants.
- The lipid-lowering effect of lovastatin was not consistent across all treated patients.
Conclusions:
- Low-dose lovastatin (20 mg/day) may offer some benefit for lipid reduction in select CAPD patients.
- The effectiveness of lovastatin for hyperlipidemia in CAPD patients is variable.
- Further research is needed to optimize lipid management strategies in CAPD.
Abstract:
Increased incidence of cardiovascular morbidity and mortality has been observed in continuous ambulatory peritoneal dialysis (CAPD) patients. Hyperlipemia is an important etiologic factor in the pathogenesis of coronary artery disease. Lovastatin has been shown to effectively lower both the serum total cholesterol and triglyceride levels, the most common abnormalities in these patients. In a retrospective study we assessed the lipid-lowering effects of lovastatin (20 mg/day) in 8 CAPD patients whose serum cholesterol and/or triglycerides remained greater than 240 mg/dL, despite a low cholesterol diet. At 6 months of lovastatin therapy, moderate reductions in total cholesterol and triglyceride levels were observed in 2 patients. Although 20 mg/day of lovastatin were well tolerated, the treatment was not universally effective in lowering the serum cholesterol and triglyceride levels.